

A comprehensive compilation of hard-to-find news/company announcements of the last 7 days, weekly stock price changes and the latest quarter's financial performance of companies in Japan's Life Science sector.

[Last 7 Days' News](#) | [Weekly Stock Movement](#) | [Gainers & Decliners](#) | [Latest Quarter Financial Performance](#)

Table of Contents

Company News: By Company Name	1
Company News: By Industry	4
Company News: By News Category	7
Stock Analysis - Top Gainers and Decliners in Japan Life Science Sector	12
Financial Performance of Japan Life Science Sector	13

SECTION A: NEWS

Companies Covered in News:

3 D Matrix Ltd | Acucela Inc. | AnGes MG, Inc. | ARKRAY Inc. | Astellas Pharma Inc. | Chugai Pharmaceutical Co. Ltd. | Eisai Co. Limited | Maruho Co., Ltd. | Ono Pharmaceutical Co., Ltd. | Taisho Pharmaceutical Holdings Co., Ltd. | Takeda Pharmaceutical Company Ltd | Teva Pharmaceutical Industries Ltd. | Toshiba Medical Systems Corporation | Yamato Scientific Co. Ltd. |

Company News: By Company Name

[3 D Matrix Ltd](#) (www), (Ticker: 7777)

Absorbable Hemostat PuraStat® product registration obtained in Australia - The 3-D Matrix group is working towards commercialization of absorbable hemostat PuraStat® globally. The company announced that the subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Australia has been granted by the Australian regulatory body, Therapeutic Goods Administration (TGA). [More...](#) (January 22, 2016)

[Acucela Inc.](#) (www), (Ticker: 4589)

Kubota Ryo reduced position in Acucela Inc - Mr. Kubota Ryo has filled a SC 13D/A form regarding the company. As per Mr. Kubota Ryo's filing, the filler reported decreased stake in the company by -75.63 % to 10,250,654 shares. [More...](#) (January 22, 2016)

AnGes MG, Inc. ([www](#)), (Ticker: 4563)

Anges MG : completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment drug for atopic dermatitis in Japan - The company has announced the completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment drug for atopic dermatitis in Japan. [More...](#) (January 19, 2016)

ARKRAY Inc. ([www](#))

Establishing an integrated manufacturing system and enhancing global competitiveness Completion ceremony held for instrument factory and distribution center in the Philippines - Starting off with urine reagents, ARKRAY Industry, Inc. in the Philippines has been manufacturing in vitro diagnostic reagents since its establishment by the company as an overseas production site in September 2011. [More...](#) (January 21, 2016)

Astellas Pharma Inc. ([www](#)), (Ticker: 4503)

Astellas extends tender offer to acquire all outstanding shares of Ocata Therapeutics - Astellas is committed to transaction, acquisition of Ocata is a strategic priority - The company and Ocata Therapeutics, Inc. announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of USD8.50 per share, net to the holder in cash on February 9, 2016. [More...](#) (January 22, 2016)

Repatha® (Evolocumab) approved as first PCSK9 inhibitor in Japan for the treatment of high cholesterol - Amgen Astellas BioPharma K.K. and the company announced that Amgen Astellas received approval for the cholesterol-lowering medication Repatha® (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Japan from the Japanese Ministry of Health, Labour and Welfare. [More...](#) (January 22, 2016)

Chugai Pharmaceutical Co. Ltd. ([www](#)), (Ticker: 4519)

Chugai Pharma receives Japanese approval for osteoporosis drug, Bonviva tablet - The company and Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of Bonviva tablet 100mg (ibandronate sodium hydrate tablet), a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. (Roche) and, in Japan, by Chugai co-developed with Taisho, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 23, 2016)

Eisai Co. Limited ([www](#)), (Ticker: 4523)

U.S. FDA accepts for priority review sNDA for Eisai's anticancer agent lenvatinib seeking approval for renal cell carcinoma - The company announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) submitted by its U.S. subsidiary Eisai Inc. for Eisai's in-house developed novel anticancer agent lenvatinib mesylate (generic name, "lenvatinib") for use in the treatment of advanced or metastatic renal cell carcinoma, and granted the sNDA Priority Review status. [More...](#) (January 18, 2016)

Maruho Co., Ltd. ([www](#))

Maruho and Galderma to join forces in a strategic alliance in Japan - Maruho Co., Ltd. and Galderma Pharma S.A. announced that they have agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of prescription drugs for

dermatology in Japan, including therapies in the fields of acne and rosacea. [More...](#) (January 18, 2016)

Ono Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4528)

FDA approves new Kyprolis® (Carfilzomib) combination therapy for the treatment of patients with relapsed or refractory multiple myeloma - Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. [More...](#) (January 22, 2016)

Taisho Pharmaceutical Holdings Co., Ltd. ([www](#)), (Ticker: 4581)

Agent for Osteoporosis approved in Japan "Bonviva® Tablet" - Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of ibandronate sodium hydrate tablet [brand name: Bonviva® Tablet 100mg (Bonviva Tablet)], a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. and, in Japan, by Taisho co-developed with Chugai, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 22, 2016)

Launch of the transdermal anti-inflammatory analgesic patch formulation LOQQA® Tape - Taisho Pharmaceutical Holdings Co., Ltd. has announced that its consolidated subsidiary Taisho Pharmaceutical Co., Ltd. has decided to launch on January 21 the transdermal anti-inflammatory analgesic patch formulation LOQQA® Tape (generic names: S-flurbiprofen, mentha oil) for the indication and usage of "the treatment of osteoarthritis pain and inflammation." [More...](#) (January 20, 2016)

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO® (ixazomib) - Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company Limited to perform genomic analysis on patient samples from a Phase 3 clinical trial of NINLARO® (ixazomib), an oral proteasome inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA), indicated in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. [More...](#) (January 22, 2016)

Takeda announces new drug application approval in Japan for a Haemophilus influenzae type b conjugate vaccine, "VAXEM Hib®" - Takeda Pharmaceutical Company Limited announced that the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application ("NDA") for a conjugate vaccine to prevent infections caused by Haemophilus influenzae type b (Hib) in children aged from 2 months to under 5 years of age. [More...](#) (January 22, 2016)

European Commission approves label variation for ADCETRIS® (Brentuximab Vedotin) to include data on retreatment of adult patients with relapsed or refractory hodgkin lymphoma and systemic anaplastic large cell lymphoma - Takeda Pharmaceutical Company Limited announced that the European Commission (EC) has approved a Type II variation for ADCETRIS® (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL) who previously responded to ADCETRIS and who later relapse. The decision from the EC follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2015. [More...](#) (January 22, 2016)

Takeda recognized as one of the global 100 Most Sustainable Corporations - Takeda Pharmaceuticals Company Limited is proud to be named by Corporate Knights to the 2016 Global 100

Most Sustainable Corporations in the World Index. [More...](#) (January 21, 2016)

Teva Pharmaceutical Industries Ltd. ([www](#))

United Therapeutics settles patent dispute with Teva Pharmaceuticals - Silver Spring-based United Therapeutics Corp. and Teva Pharmaceuticals USA Inc. have settled a dispute over Teva's plan to create a generic version of United Therapeutics' blockbuster pulmonary hypertension drug Remodulin, a Securities and Exchange Commission filing shows. [More...](#) (January 19, 2016)

Toshiba Medical Systems Corporation ([www](#))

Toshiba Medical Systems Corporation to bring leading-edge medical diagnostic imaging systems to Arab health 2016 - Toshiba Medical Systems Corporation (TMSC) announced that it will exhibit its latest diagnostic imaging systems at Arab Health 2016, the world's largest exhibition of medical equipment, which will be held at the Dubai International Convention & Exhibition Centre from January 25 to 28. [More...](#) (January 18, 2016)

Inviting outside investment in the business based on "Toshiba Revitalization Action Plan" - Toshiba Medical Systems Corporation has decided to work on inviting outside majority shareholder(s), in order to strengthen the financial ability to further realize our growth strategies, following the announcement of "Toshiba Revitalization Action Plan" by Toshiba Corporation. [More...](#) (January 18, 2016)

Yamato Scientific Co. Ltd. ([www](#))

New Product Information: IL603 / ILE800 - The company is pleased to announce the launch of our newly upgraded Incubator (Model: IL603/ILE800). These models are equipped with a newly developed "Refrigerator Circuit" which enables the evaporator to be less affected by frost forming (Patent Pending). [More...](#) (January 20, 2016)

[Top](#)

Company News: By Industry

Biotech

Acucela Inc. ([www](#)), (Ticker: 4589)

Kubota Ryo reduced position in Acucela Inc - Mr. Kubota Ryo has filled a SC 13D/A form regarding the company. As per Mr. Kubota Ryo's filing, the filler reported decreased stake in the company by -75.63 % to 10,250,654 shares. [More...](#) (January 22, 2016)

Yamato Scientific Co. Ltd. ([www](#))

New Product Information: IL603 / ILE800 - The company is pleased to announce the launch of our newly upgraded Incubator (Model: IL603/ILE800). These models are equipped with a newly developed "Refrigerator Circuit" which enables the evaporator to be less affected by frost forming (Patent Pending). [More...](#) (January 20, 2016)

Medical Dev/Tech/Supp

3 D Matrix Ltd ([www](#)), (Ticker: 7777)

Absorbable Hemostat PuraStat® product registration obtained in Australia - The 3-D Matrix group is working towards commercialization of absorbable hemostat PuraStat® globally. The company announced that the subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Australia has been granted by the Australian regulatory body, Therapeutic Goods Administration (TGA). [More...](#) (January 22, 2016)

ARKRAY Inc. ([www](#))

Establishing an integrated manufacturing system and enhancing global competitiveness

Completion ceremony held for instrument factory and distribution center in the Philippines -

Starting off with urine reagents, ARKRAY Industry, Inc. in the Philippines has been manufacturing in vitro diagnostic reagents since its establishment by the company as an overseas production site in September 2011. [More...](#) (January 21, 2016)

Toshiba Medical Systems Corporation ([www](#))

Toshiba Medical Systems Corporation to bring leading-edge medical diagnostic imaging systems to Arab health 2016 - Toshiba Medical Systems Corporation (TMSC) announced that it will exhibit its latest diagnostic imaging systems at Arab Health 2016, the world's largest exhibition of medical equipment, which will be held at the Dubai International Convention & Exhibition Centre from January 25 to 28. [More...](#) (January 18, 2016)

Inviting outside investment in the business based on "Toshiba Revitalization Action Plan" -

Toshiba Medical Systems Corporation has decided to work on inviting outside majority shareholder(s), in order to strengthen the financial ability to further realize our growth strategies, following the announcement of "Toshiba Revitalization Action Plan" by Toshiba Corporation. [More...](#) (January 18, 2016)

Pharmaceuticals**AnGes MG, Inc.** ([www](#)), (Ticker: 4563)

Anges MG : completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment drug for atopic dermatitis in Japan - The company has announced the completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment drug for atopic dermatitis in Japan. [More...](#) (January 19, 2016)

Astellas Pharma Inc. ([www](#)), (Ticker: 4503)

Astellas extends tender offer to acquire all outstanding shares of Ocata Therapeutics - Astellas is committed to transaction, acquisition of Ocata is a strategic priority -

The company and Ocata Therapeutics, Inc. announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of USD8.50 per share, net to the holder in cash on February 9, 2016. [More...](#) (January 22, 2016)

Repatha® (Evolocumab) approved as first PCSK9 inhibitor in Japan for the treatment of high cholesterol -

Amgen Astellas BioPharma K.K. and the company announced that Amgen Astellas received approval for the cholesterol-lowering medication Repatha® (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Japan from the Japanese Ministry of Health, Labour and Welfare. [More...](#) (January 22, 2016)

Chugai Pharmaceutical Co. Ltd. ([www](#)), (Ticker: 4519)

Chugai Pharma receives Japanese approval for osteoporosis drug, Bonviva tablet - The company and Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of Bonviva tablet 100mg (ibandronate sodium hydrate tablet), a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. (Roche) and, in Japan, by Chugai co-developed with Taisho, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 23, 2016)

Eisai Co. Limited ([www](#)), (Ticker: 4523)

U.S. FDA accepts for priority review sNDA for Eisai's anticancer agent lenvatinib seeking approval for renal cell carcinoma - The company announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) submitted by its U.S. subsidiary Eisai Inc. for Eisai's in-house developed novel anticancer agent lenvatinib mesylate (generic name, "lenvatinib") for use in the treatment of advanced or metastatic renal cell carcinoma, and granted the sNDA Priority Review status. [More...](#) (January 18, 2016)

Maruho Co., Ltd. ([www](#))

Maruho and Galderma to join forces in a strategic alliance in Japan - Maruho Co., Ltd. and Galderma Pharma S.A. announced that they have agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of prescription drugs for dermatology in Japan, including therapies in the fields of acne and rosacea. [More...](#) (January 18, 2016)

Ono Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4528)

FDA approves new Kyprolis® (Carfilzomib) combination therapy for the treatment of patients with relapsed or refractory multiple myeloma - Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. [More...](#) (January 22, 2016)

Taisho Pharmaceutical Holdings Co., Ltd. ([www](#)), (Ticker: 4581)

Agent for Osteoporosis approved in Japan "Bonviva® Tablet" - Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of ibandronate sodium hydrate tablet [brand name: Bonviva® Tablet 100mg (Bonviva Tablet)], a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. and, in Japan, by Taisho co-developed with Chugai, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 22, 2016)

Launch of the transdermal anti-inflammatory analgesic patch formulation LOQQA® Tape - Taisho Pharmaceutical Holdings Co., Ltd. has announced that its consolidated subsidiary Taisho Pharmaceutical Co., Ltd. has decided to launch on January 21 the transdermal anti-inflammatory analgesic patch formulation LOQQA® Tape (generic names: S-flurbiprofen, mentha oil) for the indication and usage of "the treatment of osteoarthritis pain and inflammation." [More...](#) (January 20, 2016)

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO® (ixazomib) - Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company Limited to perform genomic analysis on patient samples

from a Phase 3 clinical trial of NINLARO® (ixazomib), an oral proteasome inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA), indicated in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. [More...](#) (January 22, 2016)

Takeda announces new drug application approval in Japan for a Haemophilus influenzae type b conjugate vaccine, "VAXEM Hib®" - Takeda Pharmaceutical Company Limited announced that the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application ("NDA") for a conjugate vaccine to prevent infections caused by Haemophilus influenzae type b (Hib) in children aged from 2 months to under 5 years of age. [More...](#) (January 22, 2016)

European Commission approves label variation for ADCETRIS® (Brentuximab Vedotin) to include data on retreatment of adult patients with relapsed or refractory hodgkin lymphoma and systemic anaplastic large cell lymphoma - Takeda Pharmaceutical Company Limited announced that the European Commission (EC) has approved a Type II variation for ADCETRIS® (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL) who previously responded to ADCETRIS and who later relapse. The decision from the EC follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2015. [More...](#) (January 22, 2016)

Takeda recognized as one of the global 100 Most Sustainable Corporations - Takeda Pharmaceuticals Company Limited is proud to be named by Corporate Knights to the 2016 Global 100 Most Sustainable Corporations in the World Index. [More...](#) (January 21, 2016)

Teva Pharmaceutical Industries Ltd. ([www](#))

United Therapeutics settles patent dispute with Teva Pharmaceuticals - Silver Spring-based United Therapeutics Corp. and Teva Pharmaceuticals USA Inc. have settled a dispute over Teva's plan to create a generic version of United Therapeutics' blockbuster pulmonary hypertension drug Remodulin, a Securities and Exchange Commission filing shows. [More...](#) (January 19, 2016)

[Top](#)

Company News: By News Category

Awards/ Achievements

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Takeda recognized as one of the global 100 Most Sustainable Corporations - Takeda Pharmaceuticals Company Limited is proud to be named by Corporate Knights to the 2016 Global 100 Most Sustainable Corporations in the World Index. [More...](#) (January 21, 2016)

Changes in Shareholding

Astellas Pharma Inc. ([www](#)), (Ticker: 4503)

Astellas extends tender offer to acquire all outstanding shares of Ocata Therapeutics - Astellas is committed to transaction, acquisition of Ocata is a strategic priority - The company and Ocata Therapeutics, Inc. announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of USD8.50 per share, net to the holder in cash on February

9, 2016. [More...](#) (January 22, 2016)

Contracts/Deals

Maruho Co., Ltd. ([www](#))

Maruho and Galderma to join forces in a strategic alliance in Japan - Maruho Co., Ltd. and Galderma Pharma S.A. announced that they have agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of prescription drugs for dermatology in Japan, including therapies in the fields of acne and rosacea. [More...](#) (January 18, 2016)

Court Hearing (Litigation)

Teva Pharmaceutical Industries Ltd. ([www](#))

United Therapeutics settles patent dispute with Teva Pharmaceuticals - Silver Spring-based United Therapeutics Corp. and Teva Pharmaceuticals USA Inc. have settled a dispute over Teva's plan to create a generic version of United Therapeutics' blockbuster pulmonary hypertension drug Remodulin, a Securities and Exchange Commission filing shows. [More...](#) (January 19, 2016)

Expansion/Diversification

ARKRAY Inc. ([www](#))

Establishing an integrated manufacturing system and enhancing global competitiveness Completion ceremony held for instrument factory and distribution center in the Philippines - Starting off with urine reagents, ARKRAY Industry, Inc. in the Philippines has been manufacturing in vitro diagnostic reagents since its establishment by the company as an overseas production site in September 2011. [More...](#) (January 21, 2016)

General

Toshiba Medical Systems Corporation ([www](#))

Toshiba Medical Systems Corporation to bring leading-edge medical diagnostic imaging systems to Arab health 2016 - Toshiba Medical Systems Corporation (TMSC) announced that it will exhibit its latest diagnostic imaging systems at Arab Health 2016, the world's largest exhibition of medical equipment, which will be held at the Dubai International Convention & Exhibition Centre from January 25 to 28. [More...](#) (January 18, 2016)

Investments

Toshiba Medical Systems Corporation ([www](#))

Inviting outside investment in the business based on "Toshiba Revitalization Action Plan" - Toshiba Medical Systems Corporation has decided to work on inviting outside majority shareholder(s), in order to strengthen the financial ability to further realize our growth strategies, following the announcement of "Toshiba Revitalization Action Plan" by Toshiba Corporation. [More...](#) (January 18, 2016)

Joint Ventures

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO® (ixazomib) - Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company Limited to perform genomic analysis on patient samples from a Phase 3 clinical trial of NINLARO® (ixazomib), an oral proteasome inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA), indicated in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. [More...](#) (January 22, 2016)

New Products

Taisho Pharmaceutical Holdings Co., Ltd. ([www](#)), (Ticker: 4581)

Launch of the transdermal anti-inflammatory analgesic patch formulation LOQOA® Tape - Taisho Pharmaceutical Holdings Co., Ltd. has announced that its consolidated subsidiary Taisho Pharmaceutical Co., Ltd. has decided to launch on January 21 the transdermal anti-inflammatory analgesic patch formulation LOQOA® Tape (generic names: S-flurbiprofen, mentha oil) for the indication and usage of "the treatment of osteoarthritis pain and inflammation." [More...](#) (January 20, 2016)

Yamato Scientific Co. Ltd. ([www](#))

New Product Information: IL603 / ILE800 - The company is pleased to announce the launch of our newly upgraded Incubator (Model: IL603/ILE800). These models are equipped with a newly developed "Refrigerator Circuit" which enables the evaporator to be less affected by frost forming (Patent Pending). [More...](#) (January 20, 2016)

Patent/Trademark/License/Approval

3 D Matrix Ltd ([www](#)), (Ticker: 7777)

Absorbable Hemostat PuraStat® product registration obtained in Australia - The 3-D Matrix group is working towards commercialization of absorbable hemostat PuraStat® globally. The company announced that the subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Australia has been granted by the Australian regulatory body, Therapeutic Goods Administration (TGA). [More...](#) (January 22, 2016)

Astellas Pharma Inc. ([www](#)), (Ticker: 4503)

Repatha® (Evolocumab) approved as first PCSK9 inhibitor in Japan for the treatment of high cholesterol - Amgen Astellas BioPharma K.K. and the company announced that Amgen Astellas received approval for the cholesterol-lowering medication Repatha® (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Japan from the Japanese Ministry of Health, Labour and Welfare. [More...](#) (January 22, 2016)

Chugai Pharmaceutical Co. Ltd. ([www](#)), (Ticker: 4519)

Chugai Pharma receives Japanese approval for osteoporosis drug, Bonviva tablet - The company and Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of Bonviva tablet 100mg (ibandronate sodium hydrate tablet), a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. (Roche) and, in Japan, by Chugai co-developed with Taisho, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#)

(January 23, 2016)

Eisai Co. Limited ([www](#)), (Ticker: 4523)

U.S. FDA accepts for priority review sNDA for Eisai's anticancer agent lenvatinib seeking approval for renal cell carcinoma - The company announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) submitted by its U.S. subsidiary Eisai Inc. for Eisai's in-house developed novel anticancer agent lenvatinib mesylate (generic name, "lenvatinib") for use in the treatment of advanced or metastatic renal cell carcinoma, and granted the sNDA Priority Review status. [More...](#) (January 18, 2016)

Ono Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4528)

FDA approves new Kyprolis® (Carfilzomib) combination therapy for the treatment of patients with relapsed or refractory multiple myeloma - Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. [More...](#) (January 22, 2016)

Taisho Pharmaceutical Holdings Co., Ltd. ([www](#)), (Ticker: 4581)

Agent for Osteoporosis approved in Japan "Bonviva® Tablet" - Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of ibandronate sodium hydrate tablet [brand name: Bonviva® Tablet 100mg (Bonviva Tablet)], a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. and, in Japan, by Taisho co-developed with Chugai, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 22, 2016)

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Takeda announces new drug application approval in Japan for a Haemophilus influenzae type b conjugate vaccine, "VAXEM Hib®" - Takeda Pharmaceutical Company Limited announced that the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application ("NDA") for a conjugate vaccine to prevent infections caused by Haemophilus influenzae type b (Hib) in children aged from 2 months to under 5 years of age. [More...](#) (January 22, 2016)

European Commission approves label variation for ADCETRIS® (Brentuximab Vedotin) to include data on retreatment of adult patients with relapsed or refractory hodgkin lymphoma and systemic anaplastic large cell lymphoma - Takeda Pharmaceutical Company Limited announced that the European Commission (EC) has approved a Type II variation for ADCETRIS® (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL) who previously responded to ADCETRIS and who later relapse. The decision from the EC follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2015. [More...](#) (January 22, 2016)

Research & Development

AnGes MG, Inc. ([www](#)), (Ticker: 4563)

Anges MG : completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment drug for atopic dermatitis in Japan - The company has announced the completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment

drug for atopic dermatitis in Japan. [More...](#) (January 19, 2016)

Sale/Purchase of Company Stakes

Acucela Inc. ([www](#)), (Ticker: 4589)

Kubota Ryo reduced position in Acucela Inc - Mr. Kubota Ryo has filled a SC 13D/A form regarding the company. As per Mr. Kubota Ryo's filing, the filler reported decreased stake in the company by -75.63 % to 10,250,654 shares. [More...](#) (January 22, 2016)

[Top](#)**SECTION B : STOCK PRICE CHANGES****Stock Analysis - Top Gainers and Decliners in Japan Life Science Sector**

Country	Company	Stock Price Jan 22, 2016	Stock Price Jan 19, 2016	Current Week % Chg
Top Gainers				
Japan	Aisei Pharmacy Co., Ltd (3170)	4000	3400	17.65
Japan	Daito Pharmaceutical Company Limited (4577)	2577	2444	5.44
Japan	Kawasumi Laboratories, Incorporated (7703)	910	905	0.55
Top Decliners				
Japan	Findex Inc (3649)	744	913	-18.51
Japan	GNI Group Ltd. (2160)	126	154	-18.18
Japan	Ribomic (4591)	648	789	-17.87
Japan	Carna Biosciences. (4572)	1726	2074	-16.78
Japan	MediBIC Group, Co., Ltd. (2369)	122	146	-16.44
Japan	Okamoto Glass Co., Ltd. (7746)	146	174	-16.09
Japan	Yamane Medical Corp (2144)	180	214	-15.89
Japan	GreenPeptide (4594)	400	474	-15.61
Japan	Longlife Holding Co., Ltd. (4355)	262	310	-15.48
Japan	D. Western Therapeutics Institute, Inc. (4576)	395	466	-15.24

[Top](#)**SECTION C : FINANCIAL PERFORMANCE OF JAPAN LIFE SCIENCE SECTOR****C-1 Fastest Growing**

Company	Ticker	Sub-Industry	Overall Rank	Sales Growth Rank	Sales Growth %	Assets Growth Rank	Assets Growth %
Imageone Company Ltd.	2667	M-D/T/S	1	4	225.74	3	26.70
Tsuruha Company, Ltd.	3391	P	2	10	96.62	7	12.48
Ad Me Tech	7778	M-D/T/S	3	7	125.00	16	6.78
Techno Medica Co., Ltd.	6678	M-D/T/S	4	12	65.94	12	9.12
Welcia Holdings Co.Limited	3141	P	5	28	23.03	2	30.73

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies, and P = Pharmaceuticals

C-2 Most Profitable

Company	Ticker	Sub-Industry	Overall Rank	Net Income/Total Sales		Net Income/Total Assets		Net Income/Total Equity	
				Rank	Ratio	Rank	Ratio	Rank	Ratio
Santen Pharmaceutical Co., Ltd.	4536	P	1	1	72.38	1	10.26	1	14.40
Asahi Intecc Co., Ltd.	7747	M-D/T/S	2	3	22.85	2	5.03	3	7.95
Kaken Pharmaceutical Co., Ltd.	4521	P	3	4	22.62	3	4.97	5	7.23
Hoya Corporation	7741	M-D/T/S	4	5	20.11	5	3.78	12	4.72
M3 Inc	2413	HS	5	13	17.18	4	4.05	8	5.29

Note: For the sub-industry column above, HS = Health Services, M-D/T/S = Medical Devices/Technology/Supplies, and P = Pharmaceuticals

C-3 Most Efficient

Company	Ticker	Sub-Industry	Overall Rank	Total Sales/Total Assets		Total Sales/Total Equity	
				Rank	Ratio	Rank	Ratio
Kawanishi Holdings Incorporated	2689	M-D/T/S	1	6	0.75	1	5.19
Medius Holdings Company Limited	3154	M-D/T/S	2	8	0.72	3	4.44
Chuo Bussan Corporation	9852	P	3	4	0.79	8	2.27
Tsuruha Company, Ltd.	3391	P	4	3	0.86	12	1.88
Yamashita Medical Instruments Company Limited	3022	M-D/T/S	5	7	0.74	10	1.98

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies, and P = Pharmaceuticals

C-4 Most Improved

Company	Ticker	Sub - Industry	Sales Growth (Q3-Q2) %	Sales Growth (Q2-Q1) %
Data Horizon Co Ltd	3628	M-D/T/S	55.17	-71.79
Imageone Company Ltd.	2667	M-D/T/S	225.74	-76.35
Jeol Limited	6951	M-D/T/S	55.79	-49.42
Techno Medica Co., Ltd.	6678	M-D/T/S	65.94	-57.55
Trans Genic	2342	B	44.71	-61.54

Note: For the sub-industry column above, B = Biotech and M-D/T/S = Medical Devices/Technology/Supplies

C-5 Multinational Life Science Companies

Company	Ticker	Sub-Industry	Overall Rank	Foreign Sales Current Year		Foreign Sales to Total Sales %		Foreign Sales Growth %	
				Rank	Amount (in USDm)	Rank	Percent	Rank	Ratio
Sysmex Corporation	6869	M-D/T/S	1	11	1208.57	4	78.15	4	17.02
Otsuka Holdings Company Limited	4578	P	2	3	6908.82	11	56.75	7	13.21
Astellas Pharma Inc.	4503	P	3	4	6359.55	7	60.85	15	5.04
Terumo Corporation	4543	M-D/T/S	4	9	2332.30	8	59.55	10	9.99
Canon Electronics Inc.	7739	M-D/T/S	5	1	25164.60	2	80.57	28	14.85

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies and P = Pharmaceuticals

C-6 Research-Intensive Life Science Companies

Company	Ticker	Sub-Industry	Overall Rank	R&D Exp Current Year		R&D Exp to Total Sales %		R&D Exp Growth %	
				Rank	Amount (in USDm)	Rank	Percent	Rank	Ratio
Ad Me Tech	7778	M-D/T/S	1	9	213.48	3	155.34	1	103.59
Kissei Pharmaceutical Co., Ltd.	4547	P	2	13	121.41	8	20.66	13	9.64
Daiichi Sankyo Company Limited	4568	P	3	3	1597.78	7	20.74	38	-9.76
Astellas Pharma Inc.	4503	P	4	2	1731.26	13	16.56	35	-7.73
Cyberdyne Inc	7779	M-D/T/S	5	48	8.24	2	155.76	10	17.40

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies and P = Pharmaceuticals

Published by: FinGlobe Inc., **Address:** 5 Independence Way, Suite 300 Princeton, NJ 08540 USA

Phone: 1-609 514 5140 **Fax:** 1-609 514 5104

www: www.finglobedirect.com **Email:** info@finglobedirect.com

To subscribe, please visit <http://finglobedirect.com/index.php/japan-life-sciences-business-news-sunday-report>

For other publications on Japan Life Sciences Sector, please visit:

<http://finglobedirect.com/index.php/japan-life-sciences>

For our publications on global life sciences sectors, please visit finglobedirect.com.



Please follow us on:

For Japan Life Sciences companies and international companies with activities in Japan's Life Sciences sector, please send news and financial reports to: info@finglobedirect.com Thank you.

Disclaimer: *Japan Life Sciences Weekly is based on public domain information believed to be reliable, but no warranties are provided.*

Copyright © 2016 FinGlobe, Inc. USA